Genmab
Genmab A/S is an innovative biotechnology company focused on developing antibody therapeutics to improve patient care, particularly in oncology.
Company facts
- Founded
- 1999
- Headquarters
- Denmark
- CEO
- Jan G. J. Van de Winkel Ph.D.
About
Genmab A/S is an international biotechnology company rooted in science and inspired by patients. Founded in February 1999, the company's mission is dedicated to improving the lives of patients through innovative and differentiated antibody therapeutics for the treatment of cancer and other serious diseases. Genmab specializes in the development of antibody-based treatments, utilizing next-generation antibody technologies and quantitative sciences. With a commitment to innovation, Genmab has established a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators. With a vision for 2030, Genmab aspires to transform the treatment of cancer through powerful antibody medicines. The company embraces core values of passion for innovation, determination, integrity, and collaboration. Headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific. They strive to create a dynamic and inclusive environment for their employees, ensuring a unique workplace experience that fosters personal and professional growth.